Autoantibodies during alpha-interferon therapy for chronic hepatitis B

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Autoimmune reactions and autoantibody development are potential side effects of interferon (IFN) therapy.
• Chronic hepatitis B is a significant global health concern often managed with antiviral treatments like IFN.

Purpose of the Study:

• To investigate the incidence and clinical significance of autoantibody development in patients with chronic hepatitis B undergoing alpha-interferon (alpha-IFN) therapy.
• To assess the risk of clinically significant autoimmunity associated with recombinant and lymphoblastoid IFN regimens.

Main Methods:

• Sera from 32 chronic hepatitis B patients treated with alpha-IFN were analyzed for 13 different antibodies.
• Patients received either recombinant IFN (4.5 MU thrice weekly for 4 months) or lymphoblastoid IFN (5 MU/m2 thrice weekly for 6 months).
• Autoantibody levels were monitored before, during, and after IFN treatment, and correlated with treatment response and clinical outcomes.

Main Results:

• Pre-existing antinuclear antibodies (ANA) and smooth muscle antibodies were present in 15% and 3% of patients, respectively.
• ANA developed during IFN treatment in 18% of previously negative patients, with titers decreasing upon treatment cessation.
• No patients developed antibodies targeting endocrine organs or specific markers of autoimmune liver disease.
• No correlation was found between autoantibody status and response to IFN therapy.
• No patients exhibited clinical signs of autoimmune disease.

Conclusions:

• Recombinant and lymphoblastoid IFN therapy for chronic hepatitis B is associated with a low risk of clinically significant autoimmunity.
• Transient development of ANA during IFN treatment is possible but appears to be reversible and not clinically consequential.
• These IFN regimens are generally safe regarding the induction of clinically relevant autoimmune conditions in chronic hepatitis B patients.